Stanbio Reagents Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 30 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.30 M
as on 03-07-2024
- Revenue 4.01%
(FY 2023)
- Profit 23.22%
(FY 2023)
- Ebitda 32.79%
(FY 2023)
- Net Worth 4.66%
(FY 2023)
- Total Assets -2.49%
(FY 2023)
About Stanbio Reagents
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.30 M.
Piyali Chowdhury and Suman Chowdhury serve as directors at the Company.
- CIN/LLPIN
U24232WB1993PTC061279
- Company No.
061279
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Stanbio Reagents Pvt Ltd offer?
Stanbio Reagents Pvt Ltd offers a wide range of products and services, including Laboratory & Lab Equipment, Laboratory Bath, Laboratory Burners, Distilling Apparatus, Water Baths, Laboratory Autoclave & Sterilizers, Instrument Sterilizer, Vertical Autoclave, Cabinet Furniture, Storage Cabinets.
Who are the key members and board of directors at Stanbio Reagents?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyali Chowdhury  | Director | 01-Jun-2007 | Current |
| Suman Chowdhury | Director | 29-Dec-1993 | Current |
Financial Performance of Stanbio Reagents.
Stanbio Reagents Pvt Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 4.01% increase. The company also saw a substantial improvement in profitability, with a 23.22% increase in profit. The company's net worth moved up by a moderate rise of 4.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stanbio Reagents?
In 2023, Stanbio Reagents had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 16 Mar 1995 | ₹0.30 M | Open |
How Many Employees Work at Stanbio Reagents?
Unlock and access historical data on people associated with Stanbio Reagents, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stanbio Reagents, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stanbio Reagents's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
